Article
Insights And Considerations From The Invalidation Case As To Ruxolitinib
Ruxolitinib, a selective JAK1/JAK2 inhibitor developed by Incyte Corporation, works by blocking the JAK-STAT signalling pathway, which is closely associated with the pathogenesis of various inflammatory diseases and myeloproliferative neoplasms (MPNs).
IP March